Introduction and Objective: To assess real-world glycemic outcomes and identify predictors of composite target achievement (time in range of 70-180 mg/dL TIR70% and time below range of 70 mg/dL TBR70 4%) during the initial 12 months of open-source Android artificial pancreas system (AAPS) use among type 1 diabetes mellitus (T1D). Methods: T1D people who had used AAPS for ≥12 months were included. Continuous glucose monitoring (CGM) metrics were calculated at 3, 6 and 12 months after initiation. Logistic regression model was used to explore factors associated with achieving the composite target at 12 months. Results: Between January 2023 and December 2025, 148 participants were enrolled, comprising 104 adults and 44 children/adolescents with the median age of 33.6ys and 11.5ys, duration of 6.1ys and 1.7ys. Available mean glycated hemoglobin A1c was 7.4±1.5% at baseline and dropped by 1% after 12 months to 6.4±0.9% (P 0.001). Mean TIR values at 3, 6 and 12 months were 79.6%, 77.5% and 76.9%, respectively, while corresponding TBR70 were 4.6%, 4.4% and 4.9%. The proportion of participants achieving the composite target was 39.9% at 3 months and slightly declined to 35.1% and 33.8% at 6 and 12 months, respectively, yet no significant difference was observed (P = 0.54). Logistic regression analysis showed that older age (OR = 1.03, P = 0.04) and greater time spent in automation mode (OR = 1.04, P = 0.02) were independently associated with achieving the composite target at 12 months. Conclusion: The open-source AAPS demonstrated sustained effectiveness in improving glycemic control in individuals with T1D. Older age and greater use of automation were key predictors of achieving the composite glycemic target. Disclosure Q. Lin: None. Y. Zhou: None. Y. Ni: None. Z. Lin: None. D. Yang: None. H. Deng: None. X. Yang: None. W. Xu: None. J. Yan: None. Funding Noncommunicable Chronic Diseases-National Science and Technology Major Project (2023ZD0508200, 2023ZD0508203)
Lin et al. (Fri,) studied this question.